Use of CytoSorb® hemoadsorption column during prolonged cardiopulmonary bypass in complex cardiac surgery patient
Marianne Alarie et al. J Cardiothorac Surg. 2022.
Hide details
J Cardiothorac Surg
. 2022 Jul 7;17(1):172.
doi: 10.1186/s13019-022-01922-7.
Authors
Marianne Alarie 1 , Maggie Savelberg 2 , Danika Vautour 2 , Igo B Ribeiro 2
Affiliations
1 Kingston Health Sciences Centre, Kingston, ON, Canada. marianne.alarie@kingstonhsc.ca.
2 Kingston Health Sciences Centre, Kingston, ON, Canada.
PMID: 35799205
DOI: 10.1186/s13019-022-01922-7
Cite
Abstract
Background: Complex cardiac surgery and prolonged cardiopulmonary bypass are associated with significant activation of the systemic inflammatory response system. Pro-inflammatory cytokines, oxygen free radicals and complement activation products contribute to postoperative complications and multiorgan injury. CytoSorb® hemoadsorption therapy has been suggested to alleviate the hyperinflammatory response triggered by cardiopulmonary bypass during cardiac surgery.
Case presentation: We describe the use of CytoSorb® hemoadsorption therapy in a 61-year-old male presenting for aortic valve replacement, mitral valve replacement, tricuspid valve repair, coronary artery bypass grafting and left atrial appendage clip.
Conclusion: We were able to demonstrate that CytoSorb® use during cardiopulmonary bypass may be a safe and feasible adjunct therapy that may contribute to improved postoperative outcomes in a patient with complex cardiac disease.
Keywords: Bypass; Case report; CytoSorb; Cytokines; Hemoadsorption; Inflammation.
